Source: Clinical Infectious Diseases. Unidades: FCFRP, FMRP
Subjects: NEUROCISTICERCOSE, ANTIPARASITÁRIOS, ANTI-HELMÍNTICOS, CISTOS
ABNT
ARROYO, Gianfranco; BUSTOS, Javier A.; LESCANO, Andres G.; et al. Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis. Clinical Infectious Diseases, Cary, v. 69, n. 11, p. 1996-2002, 2019. Disponível em: < http://dx.doi.org/10.1093/cid/ciz085 > DOI: 10.1093/cid/ciz085.APA
Arroyo, G., Bustos, J. A., Lescano, A. G., Gonzales, I., Saavedra, H., Rodriguez, S., et al. (2019). Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis. Clinical Infectious Diseases, 69( 11), 1996-2002. doi:10.1093/cid/ciz085NLM
Arroyo G, Bustos JA, Lescano AG, Gonzales I, Saavedra H, Rodriguez S, Pretell EJ, Bonato PS, Lanchote VL, Takayanagui OM, Horton J, Gonzalez AE, Gilman RH, Garcia HH. Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis [Internet]. Clinical Infectious Diseases. 2019 ; 69( 11): 1996-2002.Available from: http://dx.doi.org/10.1093/cid/ciz085Vancouver
Arroyo G, Bustos JA, Lescano AG, Gonzales I, Saavedra H, Rodriguez S, Pretell EJ, Bonato PS, Lanchote VL, Takayanagui OM, Horton J, Gonzalez AE, Gilman RH, Garcia HH. Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis [Internet]. Clinical Infectious Diseases. 2019 ; 69( 11): 1996-2002.Available from: http://dx.doi.org/10.1093/cid/ciz085